Your browser doesn't support javascript.
loading
Comparative Pharmacokinetics of Commercially Available Cannabidiol Isolate, Broad-Spectrum, and Full-Spectrum Products.
Berthold, Erin C; Kamble, Shyam H; Kanumuri, Siva Rama Raju; Kuntz, Michelle A; Senetra, Alexandria S; Chiang, Yi-Hua; McMahon, Lance R; McCurdy, Christopher R; Sharma, Abhisheak.
Afiliação
  • Berthold EC; Department of Pharmaceutics, University of Florida College of Pharmacy, Gainesville, FL, USA.
  • Kamble SH; Department of Pharmaceutics, University of Florida College of Pharmacy, Gainesville, FL, USA.
  • Kanumuri SRR; Translational Drug Development Core, University of Florida Clinical and Translational Science Institute, Gainesville, FL, USA.
  • Kuntz MA; Department of Pharmaceutics, University of Florida College of Pharmacy, Gainesville, FL, USA.
  • Senetra AS; Translational Drug Development Core, University of Florida Clinical and Translational Science Institute, Gainesville, FL, USA.
  • Chiang YH; Department of Pharmaceutics, University of Florida College of Pharmacy, Gainesville, FL, USA.
  • McMahon LR; Department of Pharmaceutics, University of Florida College of Pharmacy, Gainesville, FL, USA.
  • McCurdy CR; Department of Pharmaceutics, University of Florida College of Pharmacy, Gainesville, FL, USA.
  • Sharma A; Department of Pharmacodynamics, University of Florida College of Pharmacy, Gainesville, FL, USA.
Eur J Drug Metab Pharmacokinet ; 48(4): 427-435, 2023 Jul.
Article em En | MEDLINE | ID: mdl-37337087
ABSTRACT
BACKGROUND AND

OBJECTIVES:

A wide variety of products containing cannabidiol (CBD) are available on the commercial market. One of the most common products, CBD oil, is administered to self-treat a variety of conditions. These oils are available as CBD isolate, broad-spectrum [all terpenes and minor cannabinoids except Δ-9-tetrahydrocannabinol (THC)], or full-spectrum (all terpenes and minor cannabinoids with THC < 0.3% dried weight) products. A systematic pharmacokinetic study was performed to determine whether there are differences in the pharmacokinetic parameters and systemic exposure of CBD after oral dosing as an isolate, broad-spectrum, or full-spectrum product.

METHODS:

Male and female Sprague Dawley rats were treated with a single, equivalent oral dose of CBD delivered as isolate, broad-spectrum, or full-spectrum product. An additional study using an in-house preparation of CBD isolate plus 0.2% THC was performed. A permeability assay was also conducted to investigate whether the presence of THC alters the intestinal permeability of CBD.

RESULTS:

There was an increase in the oral bioavailability of CBD (12% and 21% in male and female rats, respectively) when administered as a full-spectrum product compared with the isolate and broad-spectrum products. There was no difference in the bioavailability of CBD between the commercially available full-spectrum formulation (3.1% CBD; containing 0.2% THC plus terpenes and other minor cannabinoids) versus the in-house preparation of CBD full-spectrum (CBD isolate 3.2% plus 0.2% THC isolate). In vitro permeability assays demonstrated that the presence of THC increases permeability of CBD while also decreasing efflux through the gut wall.

CONCLUSIONS:

The presence of 0.2% THC increased the oral bioavailability of CBD in male and female rats, indicating that full-spectrum products may produce increased effectiveness of CBD due to a greater exposure available systemically.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Canabidiol / Canabinoides Limite: Animals Idioma: En Revista: Eur J Drug Metab Pharmacokinet Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Canabidiol / Canabinoides Limite: Animals Idioma: En Revista: Eur J Drug Metab Pharmacokinet Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos